Evolent Health, Inc (EVH)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-06. ClinicalTrials.gov
Dilution Risk
LOW DILUTION RISKDilution score: 23/100 (LOW), cash runway not available
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 14.93% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- 3 Reasons to Avoid EVH and 1 Stock to Buy Instead
- TransPerfect Selected by Evolent for Enterprise-Wide Telephonic Interpretation
- Q2 Healthcare Technology for Providers Earnings: Evolent Health (NYSE:EVH) Impresses
- 1 Value Stock with Promising Prospects and 2 That Underwhelm
- 5 Must-Read Analyst Questions From Evolent Health’s Q2 Earnings Call
- Evolent Health (EVH) Q2 2026 Earnings Call Transcript
- Evolent Health Inc (EVH) (Q2 2026) Earnings Call Highlights: Revenue Surges 31% and Guidance ...
- Compared to Estimates, Evolent Health (EVH) Q2 Earnings: A Look at Key Metrics
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Evolent Health, Inc.
Full EVH Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.